Lampalizumab
Intravitreal | |
---|---|
ATC code |
|
Identifiers | |
CAS Number | |
IUPHAR/BPS | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C2068H3214N546O676S13 |
Molar mass | 46958.39 g·mol−1 |
Lampalizumab (
One of the two Phase 3 clinical trials (Spectri) was interrupted on September 8, 2017 due to failure to meet primary end point.[3] The second Phase 3 clinical trial (Chroma) also failed to meet its primary end point.[4]
These two failures have called into question whether complement inhibition is a sound strategy for geographic atrophy.[5]
References
- ^ World Health Organization (2012). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107" (PDF). WHO Drug Information. 26 (2).
- ^ "Statement On A Nonproprietary Name Adopted By The USAN Council - Lampalizumab" (PDF). American Medical Association.
- ^ "Roche provides update on first lampalizumab phase III study for geographic atrophy, an advanced form of age-related macular degeneration". www.roche.com. Retrieved 2017-09-14.
- ^ "Statement on Chroma Study". www.roche.com. Retrieved 2017-11-10.
- S2CID 9682962.